MedTrace Logo

Efficacy of 200 IU OnabotulinumtoxinA in Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment

NCT06408051 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-12-27

No results posted yet for this study

Summary

This study aimed to assess the efficacy and safety of onabotulinumtoxinA (botulinum toxin type A) in patients with idiopathic overactive bladder (OAB) and urinary incontinence who had previously failed to respond to anticholinergic treatment. Additionally, we examined the impact of significant reductions in bladder wall thickness on therapeutic outcomes.

Conditions

  • Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment

Interventions

PROCEDURE

Injection of onabotulinumtoxinA into the bladder wall

BTX was injected into the detrusor muscles at 20 sites

Sponsors & Collaborators

  • Hisar Intercontinental Hospital

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-01-31
Completion
2023-07-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06408051 on ClinicalTrials.gov